David A. Siegel Ptc Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ptc Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 393,242 shares of PTCT stock, worth $12 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
393,242
Previous 189,842
107.14%
Holding current value
$12 Million
Previous $5.23 Million
118.64%
% of portfolio
0.03%
Previous 0.01%
Shares
23 transactions
Others Institutions Holding PTCT
# of Institutions
198Shares Held
83.7MCall Options Held
192KPut Options Held
129K-
Vanguard Group Inc Valley Forge, PA9.37MShares$287 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.9MShares$272 Million0.05% of portfolio
-
Black Rock Inc. New York, NY7.57MShares$231 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.42MShares$227 Million3.47% of portfolio
-
Armistice Capital, LLC New York, NY6.76MShares$207 Million2.68% of portfolio
About PTC THERAPEUTICS, INC.
- Ticker PTCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,541,000
- Market Cap $2.19B
- Description
- PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on...